What is driving the pre-market move in 1093.HK stock?

The pre-market drop reflects news of a licensing deal with AstraZeneca and heavy volume. Traders are re-pricing global rights for CSPC's weight-loss peptides, causing short-term profit-taking and higher intraday volatility in 1093.HK stock.

What is Meyka AI's outlook for 1093.HK stock?

Meyka AI's forecast model projects a yearly level of **HK$11.49**, implying **+19.66%** versus the current **HK$9.60**. The model and grade (66.68, B, HOLD) flag upside but recommend monitoring regulatory and deal milestones for 1093.HK stock.

Are valuation metrics supportive for 1093.HK stock?

CSPC posts EPS **HK$0.38**, PE **28.13**, PB **3.27**, and dividend yield **2.25%**. These place 1093.HK stock roughly in line with the Healthcare sector, but growth and receivables timing remain near-term risks.

What trading signals should investors watch for 1093.HK stock?

Watch intraday volume, RSI near **69.45**, and price relative to the upper Bollinger band. A break below **HK$9.32** or a sustained move above **HK$10.96** will clarify direction for 1093.HK stock.

HK Stocks

1093.HK CSPC Pharma (HKSE) down 9.00% pre-market 31 Jan 2026: AstraZeneca impact

ByDanny Kontos January 31, 2026January 31, 2026

The most active Hong Kong stock this pre-market session is CSPC Pharmaceutical Group Limited (1093.HK stock), trading at HK$9.60, down 9.00% after heavy volume. Shares opened at HK$10.94 and are trading between HK$9.32 and HK$10.96 so far. Volume is already 570,493,236 shares, about 5.04 times the daily average. The move follows news of a licensing deal with AstraZeneca and triggered active intraday selling and position reshuffling on the HKSE in Hong Kong.